Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)
Status:
Withdrawn
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
Though patients whose tumors harbor EGFR T790M mutation appear to benefit from rociletinib,
there is a need to understand the molecular mechanisms that lead to primary and acquired
resistance to rociletinib. The investigators propose to conduct a clinical trial of
rociletinib of patients with EGFR-mutant NSCLC with activating EGFR mutations (including exon
19 deletion or L858R mutation), with or without EGFR T790M mutation. In these patients,
pre-treatment and post-progression biopsy specimens will be subjected to genomic analysis to
fully understand the clonal evolution and the molecular mechanisms underpinning treatment
resistance.